Search
Boehringer_Ingelheim_company_profile_2015.pdf
Boehringer_Ingelheim_Company_Profile_2017.pdf
Global language learning platform for our people
One global learning platform for languages, countless opportunities to grow your career
Development Biotechnology sustainable cell culture
Boehringer Ingelheim refines its bioprocess technology operations in Animal Health with greater focus on environmental sustainability to reduce footprint
Interview Dr Mehdi Shahidi
Interview with Dr Mehdi Shahidi, Chief Medical Officer and Head of the Corporate Division Medicine at Boehringer Ingelheim
emperor-preserved-heart-failure-toplineresults
Positive, top-line results announced from the EMPEROR-Preserved Phase III trial in adults with heart failure with preserved ejection fraction
collaboration-kings-college-london
Boehringer Ingelheim and the IoPPN at King’s College London partner to progress new therapeutic concepts in major depressive disorder and schizophrenia
Aservo EquiHaler wins Pharmapack Award 2021
Boehringer Ingelheim’s Aservo® EquiHaler® is recognized in the 2021 Pharmapack Awards
World water day 2019
Boehringer Ingelheim started a social project in Mexico to preserve the aquifer and to ensure the water supply for dog shelters. Rainwater collector will save 180,000 liters of rainwater every year.
Supply Chain Scholarship for Cowtribe
A supply chain course we sponsored boosted the career of Latifa Saaka
Gallimune® / Gallivac® / Volvac®
For vaccination of healthy chickens against diseases caused by the included antigens.
Facts about the INPULSIS™ trials
We support non-linear career paths.
Emmanuelle Clerisme-Beaty talks about making breakthroughs in the rare disease space.“I’m here to let patients know that they're not alone”
Partnership for new liver disease treatments with Ribo
Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases
Targeting Tumor Stroma
Boehringer Ingelheim’s research approach in stromal biology may lead to new medicines that will change the face of cancer and give new hope to patients
Nerandomilast primary endpoint phase-3 FIBRONEER-IPF met
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study